Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Gut Liver ; 16(2): 259-268, 2022 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-34810296

RESUMEN

BACKGROUND/AIMS: Polyethylene glycol (PEG)-based bowel preparations are effective cleansing agents for colonoscopy. However, they require relatively large volumes to be used even with agents such as 2 L PEG with ascorbate (2LPEG). This phase 3, randomized, single-blinded, multicenter, parallel-group study compared the efficacy of 1 L PEG with high-dose ascorbate, TJP-008, to 2LPEG. METHODS: Patients undergoing colonoscopy were randomized (1:1:1) to receive TJP-008 as 1-day split dose (TJP-008-1) or 2-day split dose (TJP-008-2) regimen or to receive 2LPEG as a 2-day split dose regimen. Cleansing efficacy was evaluated using the Harefield Cleansing Scale. The primary endpoint was overall bowel cleansing success. Full analysis set (FAS) and per protocol set (PPS) analyses were performed. RESULTS: Of the 314 screened patients, efficacy was assessed in the following patient numbers (FAS/PPS): total (293/285), TJP-008-1 (98/94), TJP-008-2 (97/95), and 2LPEG (98/96). FAS revealed noninferiority between TJP-008 and 2LPEG with regard to overall success (TJP-008-2, 99.0%; TJP-008-1, 95.9%; 2LPEG, 94.9%; p=0.100 and p=0.733, respectively). PPS also showed noninferiority (p=0.721 and p=0.211, respectively). However, the PPS analyses showed a higher bowel cleansing score for TJP-008-2 for high-quality cleansing in the right colon (TJP-008-2 83.2% vs 2LPEG 62.5%; p=0.005). CONCLUSIONS: TJP-008 is a new low-volume cleansing agent with a colon cleansing efficacy comparable to that of standard 2LPEG that exhibits significant safety and tolerability.


Asunto(s)
Catárticos , Polietilenglicoles , Ácido Ascórbico , Colon , Colonoscopía/métodos , Humanos
2.
Sci Rep ; 3: 1629, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23568217

RESUMEN

Oxymatrine is a traditional Chinese herbal product that exhibits anti-inflammatory effects in models of heart, brain and liver injury. We investigated the impact of oxymatrine in an acute model of intestinal injury and inflammation. Oxymatrine significantly decreased LPS-induced NF-κB-driven luciferase activity, correlating with diminished induction of Cxcl2, Tnfα and Il6 mRNA expression in rat IEC-6 and murine BMDC. Although oxymatrine decreased LPS-induced p65 nuclear translocation and binding to the Cxcl2 gene promoter, this effect was independent of IκBα degradation/phosphorylation. DSS-induced weight loss and histological damage were ameliorated in oxymatrine-treated C57BL/6-WT-mice. While this effect correlated with reduced colonic Il6 and Il1ß mRNA accumulation, global NF-κB activity as measured in NF-κB(EGFP) mice was unaffected. Our data demonstrate that oxymatrine reduces LPS-induced NF-κB nuclear translocation and activity independently of IκBα status, prevents intestinal inflammation through blockade of inflammatory signaling and ameliorates overall intestinal inflammation in vivo.


Asunto(s)
Alcaloides/farmacología , Núcleo Celular/metabolismo , Colitis/metabolismo , Medicamentos Herbarios Chinos/farmacología , FN-kappa B/metabolismo , Quinolizinas/farmacología , Alcaloides/administración & dosificación , Animales , Línea Celular , Colitis/inducido químicamente , Colitis/tratamiento farmacológico , Colitis/inmunología , Colitis/patología , Citocinas/metabolismo , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Sulfato de Dextran/efectos adversos , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/administración & dosificación , Activación Enzimática/efectos de los fármacos , Proteínas I-kappa B/metabolismo , Mediadores de Inflamación/metabolismo , Lipopolisacáridos/inmunología , Ratones , Ratones Transgénicos , FN-kappa B/genética , Fosforilación , Transporte de Proteínas/efectos de los fármacos , Quinolizinas/administración & dosificación , Ratas , Factor de Transcripción ReIA/metabolismo
3.
Science ; 330(6005): 831-5, 2010 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-21051639

RESUMEN

The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial ß-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial ß-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial ß-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.


Asunto(s)
Antineoplásicos Fitogénicos/toxicidad , Camptotecina/análogos & derivados , Inhibidores Enzimáticos/farmacología , Glucuronidasa/antagonistas & inhibidores , Glucuronidasa/farmacología , Animales , Antineoplásicos Fitogénicos/metabolismo , Bacterias Anaerobias/efectos de los fármacos , Camptotecina/metabolismo , Camptotecina/toxicidad , Línea Celular Tumoral , Colon/efectos de los fármacos , Colon/microbiología , Colon/patología , Cristalografía por Rayos X , Diarrea/prevención & control , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/metabolismo , Escherichia coli/enzimología , Proteínas de Escherichia coli/antagonistas & inhibidores , Proteínas de Escherichia coli/química , Proteínas de Escherichia coli/aislamiento & purificación , Proteínas de Escherichia coli/metabolismo , Femenino , Glucuronidasa/química , Glucuronidasa/aislamiento & purificación , Glucuronidasa/metabolismo , Humanos , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/microbiología , Mucosa Intestinal/patología , Irinotecán , Ratones , Ratones Endogámicos BALB C , Modelos Moleculares , Profármacos/metabolismo , Profármacos/toxicidad , Conformación Proteica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA